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0.99)]. – Question: Could this difference be decreased by 
reducing cultural and language barriers?
(4) Cancers of pulmonary lobes rather than the main 
bronchus pose lower risks of LC death. Question: Could 
outcomes for main bronchus cancers be improved by 
up-skilling or referral to higher-volume centres?
(5) Greater extent of disease is strongly predictive of 
case fatality – Question: Could LC deaths be reduced by 
earlier treatment?
(6) Use of lobectomies varies – Question: Could survival 
be increased through greater use of lobectomies for 
localised NSCLC?
Conclusions: Linked cancer registry and hospital data 
can increase system-wide understanding of local 
health-service delivery and prompt discussion points 
on how to improve outcomes.
Abbreviations: APDC – Australian Patient Data 
Collection; CHeReL – Centre for Health Record Linkage; 
EOD – Extent of Disease; LC – Lung Cancer; 
NSCLC – Non-Small Cell Cancers; NSWCR – New South 
Wales Cancer Registry; OR – Relative Odds; 
SEIFA – Socio-Economic Index for Areas; SES – Socio-
Economic Status.
Key words: epidemiology; health service delivery; 
management.
Abstract
Objective: To use linked NSW Cancer Registry and 
hospital lung cancer (LC) data for raising discussion 
points on how to improve outcomes.
Design: Historical cohort – cases diagnosed in 2003-2007.
Setting: New South Wales, Australia
Outcome Measures: Relative odds (OR) of localised 
disease and resection of non-small cases (NSCLC) using 
multiple logistic regression. Comparisons of risk of 
NSCLC death using competing risk regression.
Findings: 
(1) Older patients have fewer resections of localised 
NSCLC [adjusted OR 95% CLs; 80+Vs <60 years; 0.20 
(0.14, 0.28)]. Cases with co-morbidity have fewer 
resections [adjusted OR, 0.74 (0.61, 0.90)] and have 
more conservative resections. Question: Is there the 
best balance between resection and avoiding surgery 
to accommodate frailty and co-morbidity? 
(2) Compared with public patients, the health insured: 
have higher odds of localised LC [adjusted OR, 1.23 (1.12, 
1.35] and resection for localised NSCLC [adjusted OR, 
2.08 (1.70, 2.54)]; are more likely to have lobectomies 
than wedge/segmental resections (p<0.001); and have 
a lower risk of LC death [adjusted SHR, 0.89 (0.85, 0.93)]. 
Question: Are there opportunities for improving public-
patient outcomes? 
(3) Patients born in non-English speaking countries have 
lower odds of localised disease [adjusted OR, 0.88 (0.79, 
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Introduction
Decisions in health service administration ideally are 
guided by objective evidence of local needs and service 
performance. Because an evidence gap often applies, 
varying reliance is placed on anecdotal reports and intuitive 
judgement. In this study, we explore the utility of linked 
cancer registry and hospital data to reduce the evidence 
gap and prompt questions for decision-making.
Lung cancer (LC) is used as a case study because of its 
importance as the leading cause of cancer death in NSW, 
Australia and worldwide. [1-3] While prevention through 
reducing tobacco smoking is the principal public health 
response, preventive benefits can take many years to 
materialise. [3] Although a reduction in age-standardised LC 
incidence and mortality of about 30% occurred in New South 
Wales males in the last 25 years, there was a corresponding 
133% increase for females, [1] despite concurrent decreases 
in tobacco smoking in both sexes. [3] This reflects an 
extensive lag time. Based on the lag time between smoking 
decreases and lung cancer mortality reductions in males, 
female lung cancer mortality is expected to peak soon 
before beginning to decline. [1] While continued emphasis 
on reducing tobacco smoking is critically important, 
supplementary initiatives are needed for more immediate 
gains, potentially including earlier diagnosis and improved 
treatment.
Although survival has increased, about 86% of Australian 
LC patients still die from their disease within five years of 
diagnosis. [4] The United States figure is similar at 82%. 
[5] Risk of death potentially could be reduced by earlier 
diagnosis. [5-7] Compared with localised cases, the relative 
risk of death in the five years following diagnosis is about 
1.6 for regional and 2.1 for distant stage. [5,7] Unfortunately 
there is not an accepted population-based screening test. 
[3] Early United States trial data comparing annual helical 
computed tomography screening with conventional chest 
X-ray found earlier diagnostic stage and reduced lung 
cancer mortality for high risk individuals, but confirmatory 
data are required. [6]
Increased resection could also be beneficial. National Health 
and Medical Research Council guidelines indicate surgical 
resection to be the preferred treatment for localised non-
small cell cancers (NSCLC), as do other guidelines. [8-10] 
Treatment differences are important when interpreting 
survival inequalities, but data on extent of disease (EOD) 
and treatment rarely are available from Australian cancer 
registries, which complicates interpretation of survival.
New South Wales has the only Australian state registry that 
routinely records EOD for all solid tumours. Opportunities 
exist to link NSCLC incidence and death data from the 
registry to inpatient treatment statistics, using the Centre 
for Health Record Linkage (CHeReL). The aim of this study 
is to explore the administrative utility of linked data for 
investigating associations of system-wide patient and 
tumour characteristics with: EOD at diagnosis; treatment 
by resection (localised NSCLC cases); and death from LC. 
Results are used to raise questions on how to improve 
health outcomes.
David Roder
Cancer Information and Analysis Unit
Cancer Institute NSW
Alexandria, New South Wales, Australia.
Centre for Population Health Research 
University of South Australia
Adelaide, South Australia, Australia.
Hui  You
Cancer Information and Analysis Unit
Cancer Institute NSW
Alexandria, New South Wales, Australia.
Deborah Baker 
Cancer Information and Analysis Unit
Cancer Institute NSW
Alexandria, New South Wales, Australia.
Richard Walton
Cancer Analysis and Statistics Unit
Cancer Institute NSW
Alexandria, New South Wales, Australia.
Brian McCaughan
Faculty of Medicine 
University of Sydney 
Sydney, New South Wales, Australia.
Sanchia Aranda
School of Health Sciences
University of Melbourne
Melbourne, Victoria, Australia.
Cancer Services and Information (formerly) 
Cancer Institute NSW
Alexandria, New South Wales, Australia.
David Currow
Chief Executive Officer
Cancer Institute NSW
Alexandria, New South Wales, Australia.
Correspondence:
roder@internode.on.net
Asia Pacific Journal of Health Management 2016; 11: 1 67
The extent to which characteristics associated with EOD, 
resection and LC death represent modifiable causes will 
need consideration. Nonetheless study results are expected 
to increase system-wide understanding of local health 
service delivery and provide an evidence base for guiding 
discussions on improving service outcomes.
Methods
LC incidence data for 2003 (Jan) - 2007 (Dec) from the NSW 
Cancer Registry (NSWCR) and associated death data to 
December 31, 2008 were linked to surgical resection data for 
the period from January 2003 to June 2008, extracted from 
the NSW Admitted Patient Data Collection (APDC). APDC 
data from July 2000 to June 2008 were also linked to NSWCR 
data to obtain source data on co-morbidity. Data linkage 
occurred through CHeReL using ChoiceMaker probabilistic 
linkage software. Resections were included if occurring up 
to six months after diagnosis.
The NSWCR includes population-based registry data, 
operating under authority of the NSW Public Health Act 
(1991), which mandates notification by hospitals, pathology 
laboratories, nursing homes and ancillary sources for 
invasive cancers (apart from non-melanoma skin cancers) 
diagnosed in the New South Wales population.
The APDC covers admissions to New South Wales public 
and private hospitals. NSWCR data were extracted from 
the registry for the International Classification of Diseases 
for Oncology (Version 3) (ICD-O-3) C34 topography code 
but excluding neuroendocrine tumours and non-epithelial 
cancers, such as soft tissue tumours and sarcomas, 
fibromatous and myomatous neoplasms. Cancers recorded 
only on the basis of information from death certification and 
those first diagnosed at post-mortem were also excluded. 
[3] In all, 15,014 of 15,498 bronchus and lung cancers on the 
NSWCR file were included. [3]
Cases were classified by:
•  Socio-demographic characteristics – age at diagnosis,  
 sex, country of birth, geographic remoteness of  
 residence, socio-economic status (using the ABS SEIFA  
 (Socio-Economic Index for Areas) relative socio-economic  
 disadvantage index [11]) and Local Health District of
 residence. The process involved using residential census  
 collection districts to classify by remoteness according  
 to the Australian Standard Geographical Classification  
 (major city, inner regional, outer regional, remote and  
 very remote) and to derive the SEIFA Index of Relative
 Socio-economic Disadvantage by ABS Statistical Local  
 Area using equal-population quintiles. [11]
Table 1: Relative odds (OR) (95% confidence limits) of localised extent of disease for lung cancers diagnosed in New 
South Wales in 2003-2007*
Multivariable logistic regression
CHARACTERISTIC  NUMbERS (ALL CANCERS/LOCALISED ADjUSTED OR **
 CANCERS)
Age at diagnosis. (yrs.):
<60 2255/565 1.00
60-69 3275/939 1.17 (1.03, 1.33)
70-79 3927/1210 1.34 (1.19, 1.52 )
80+ 2037/667 1.61 (1.40, 1.86)
Sex:
Male 7124/2094 1.00
Female 4370/1287 1.07 (0.98, 1.17)
Public/private status:
Public 7683/2153 1.00
Private (+ Veterans Affairs) 3636/1187 1.23 (1.12, 1.35)
Unknown 175/41 1.23 (0.83, 1.81)
Remoteness (residence):
Major city 6523/1950 1.00
Inner regional 3328/925 0.96 (0.84, 1.10)
Outer regional 1505/451 1.08 (0.88, 1.32)
Remote/very remote 138/55 1.54 (1.01, 2.35)
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CHARACTERISTIC  NUMbERS (ALL CANCERS/LOCALISED ADjUSTED OR **
 CANCERS)
SES quintile (SEIFA)
(residence):
1 (least disadvantaged) 1920/565 1.00
2 1908/547 1.00 (0.84, 1.19)
3 2404/688 1.04 (0.86, 1.26)
4 2807/823 1.08 (0.89, 1.31)
5 (most disadvantaged) 2455/758 1.15 (0.94, 1.40)
Country of birth:
Australia 7493/2223 1.00
Other-English speaking 1431/396 0.93 (0.81, 1.06)
Other-not English speaking 2395/674 0.88 (0.79, 0.99)
Unknown 175/88 2.56 (1.86, 3.52)
Lung location:
C340 (main bronchus) 1057/294 1.00
C341 (upper lobe) 4269/1502 1.48 (1.27, 1.72)
C342 (middle lobe) 480/191 1.81 (1.43, 2.28)
C343 (lower lobe) 2368/904 1.63 (1.38, 1.92)
C348 (overlapping) 125/35 1.03 (0.67, 1.56)
C349 (not specified) 3195/455 0.45 (0.38, 0.54)
Histology type:
Adenocarcinoma 3711/1014 1.00 
Squamous cell carcinoma 2020/890 1.93 (1.71, 2.18)
Large cell carcinoma 3740/910 0.89 (0.80, 0.99)
Other/unknown 2023/567 1.16 (1.02, 1.32)
Charlson co-morbidity score:
0 4639/1430 1.00
1+ 5687/1686 0.96 (0.87, 1.05)
Unknown 1168/265 0.71 (0.60, 0.83)
*Data source: NSW Cancer Registry; **Adjusted for other variables in the Table1(and Local Health District of residence). 
Note: Excludes cases with unknown extent of disease.
Table 1: Relative odds (OR) (95% confidence limits) of localised extent of disease for lung cancers diagnosed in New 
South Wales in 2003-2007* continued
•  Histology type – adenocarcinoma, squamous cell  
 carcinoma, large cell carcinoma, and other types, as  
 classified by ICD-O-3. [12]
•  Location of tumour - main bronchus and upper, middle  
 and lower pulmonary lobes. [12]
•  EOD - localised, regional and distant. [12]
•  Resection type - wedge, segmental, lobectomy and  
 pneumonectomy. [12]
•  Co-morbidity - Charlson index derived from APDC data  
 for up to five years before LC diagnosis. [13]
•  Payment status - public or private (or Veterans coverage)  
 for the payment status applying at the first hospital  
 episode for the index cancer.
•  Emergency attendance – as indicated by the urgency 
 of admission flag for admission where treatment was  
 required within 24 hours.
NSWCR and APDC data were linked by CHeReL using 
probabilistic linkage and identifiers removed before release 
for analysis. Research ethics approval was obtained [NSW 
Population and Health Services Research Ethics Committee 
Reference No. 2009/04/150].
Multiple logistic regression analysis was used to calculate 
relative odds (odds ratios) of localised compared with more 
advanced EOD at diagnosis (Table 1), and treatment of 
localised cases by resection (Figure 1) and resection type, 
adjusting for socio-demographic and clinical factors. [14] 
Multivariable competing risk regression was used to calculate 
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Figure 1: Relative odds (95% CI) of resection for localized non-small cell lung cancer diagnosed in New South Wales 
in 2003 – 2007*
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sub-hazards ratios for LC death from time of diagnosis to 
death (in months) or December 31, 2008, whichever came 
first, with deaths from other causes as the competing event. 
[14] Co-linearity assumptions were checked and log-normal
plots examined to test proportionality.
Cases with unknown extent of disease (24.2% of cases) 
were excluded from logistic regression models comparing 
localised with more advanced EOD, but were included as a 
dummy variable in competing risk regression models when 
deriving sub-hazards ratios for LC death. Missing values for
other independent variables were also included as dummy 
variables. When results of logistic regression and competing 
risk regression were checked using complete case analysis 
that excluded cases with missing values, findings were 
similar. STATA release 12 was used. [14]
Results
by socio-demographic characteristic
Age at diagnosis
Odds of localised EOD were higher for older ages (Table 
1). Older cases with localised NSCLC had fewer resections 
(Figure 1). Compared with those under 60 years, the adjusted 
relative odds of resection (95% CLs) were 0.62 (0.48, 0.82) 
and 0.20 (0.14, 0.28) for 70-79 and 80+ year olds respectively. 
Surgery also tended to be more conservative (p=0.051), the 
ratio of lobectomies to wedge resections decreasing from 
8.5 to 1 for cases less than 60 years to 4.9 to 1 for those aged 
80 years or more. The corresponding ratio of lobectomies 
to wedge and segmental resections decreased from 2.2 to 
1 to 1.8 to 1. The older the age, the higher was the risk of LC 
death (Table 2).
Sex
Females had more conservative resections, the ratio 
of lobectomies to wedge resections being 5.7 to 1 for 
females compared with 8.7 to 1 for males (p=0.050). The 
corresponding ratio of lobectomies to wedge and segmental 
resections was 1.7 to 1 and 2.2 to 1 respectively. Female 
patients had a lower risk of LC death (Table 2).
Payment status
Patients with private health insurance (or Veterans coverage) 
had higher odds of localised EOD (Table 1) and compared 
with public patients, adjusted relative odds of resection for 
localised NSCLC of 2.08 (1.70, 2.54) (Figure 1). They also had 
higher odds of lobectomy compared with wedge resection 
of 15.8 to 1 compared with 4.6 to 1 for public patients 
(p<0.001), and of lobectomy compared with wedge and 
segmental resections, of 3.2 to 1 and 1.4 to 1 respectively 
(p<0.001). The risk of LC death was lower in insured patients 
(Table 2).
Remoteness
An unexpected 54% elevation in odds of localised EOD 
occurred at presentation for residents from remote/very 
remote compared with major city areas after adjustment 
(Table 1). Odds of resection from localised NSCLC did not 
vary by remoteness (Figure 1), nor did types (p>0.200), as 
indicated by the ratio of lobectomies to wedge resections 
(p=0.329) and to wedge and segmental resections (p=0.549). 
Elevated risk of LC death in inner and outer regional than 
major city areas did not persist after co-variable adjustment 
(Table 2). Risk of LC death was not elevated in remote/very 
remote areas.
Socio-economic status (SES)
Adjusted relative odds of resection for localised NSCLC were 
lower at 0.58 (0.39, 0.87), 0.63 (0.41, 0.95) and 0.65 (0.43, 
0.99) for lower quintiles three, four and five respectively 
compared with quintile one (highest SES) (Figure 1), but 
resection types did not vary by quintile (p=0.233). SES was 
not associated with risk of LC death (Table 2).
Country of birth
Adjusted analysis indicated lower odds of localised disease 
for patients with non-English speaking than Australian 
country of birth (Table 1) and lower risk of LC death (Table 2). 
Resection types did not differ by country of birth (p=0.275).
By co-morbidity status
Cases with co-morbidity (Charlson score 1+ Vs 0) had lower 
adjusted odds of resection than other patients for localised 
NSCLC at 0.74 (0.61, 0.90) (Figure 1). The lobectomy to wedge 
resection ratios was 2.2 to 1 and 4.6 to 1 respectively, and 
the lobectomy to wedge and segmental resection ratios was
1.7 to 1 and 2.3 to 1 respectively. Higher co-morbidity was 
associated with higher risk of LC death which persisted, 
although more marginal, in multivariable models (Table 2).
by clinical characteristics
Location
Cancers of pulmonary lobes had higher odds of localised 
EOD than cancers of the main bronchus (Table 1). Higher 
adjusted relative odds of resection applied for localised 
NSCLC of the pulmonary lobes at 9.26 (5.51, 15.56), 7.56 
(4.08, 14.01) and 11.82 (6.96, 20.09) respectively, compared 
with cancers of the main bronchus (Figure 1), but with little 
difference in resection types (p=0.820). Risk of LC death was 
lower for LC in pulmonary lobes than the main bronchus 
(Table 2).
Histology type
Compared with adenocarcinomas, squamous cell lesions 
had higher and large cell lesions lower odds of localised EOD 
Using Linked Lung Cancer Registry and Hospital Data For Guiding Health Service Improvement
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Table 2: Sub-hazard ratios (SHR) (95% confidence limits) for cumulative probability of death from lung cancer
among New South Wales cases diagnosed in 2003-2007, according to patient and cancer characteristics, and
treatment by resection*
Competing risk regression
CHARACTERISTIC  NUMbERS UNADjUSTED ADjUSTED   ADjUSTED  ADjUSTED 
 (CASES/LUNG SHR SHR** SHR*** SHR****
 CANCER DEATHS)
Age at diagnosis (yrs.):
<60 2710/1874 1.00 1.00 1.00 1.00 
60-69 4047/2861 1.07 (1.02, 1.13) 1.07 (1.01, 1.13) 1.12 (1.06, 1.18) 1.11(1.05,1.17)  
70-79 5232/3951 1.28 (1.21, 1.35) 1.24 (1.17, 1.30) 1.36 (1.29, 1.44) 1.32 ( 1.25, 1.39)
80+ 3025/2396 1.59 (1.50, 1.68) 1.48 (1.39, 1.57) 1.72 (1.61, 1.83) 1.57 (1.47, 1.67)
Sex:
Male 9374/7012 1.00 1.00 1.00 1.00
Female 5640/4070 0.91 (0.88, 0.94) 0.91 (0.87, 0.95) 0.91 (0.87, 0.94) 0.92 (0.88, 0.95)
Public/private status:
Public 9891/7526 1.00 1.00 1.00 1.00 
Private (+ Veterans Affairs) 4792/3369 0.84 (0.81, 0.87) 0.81 (0.77, 0.84) 0.84 (0.81, 0.88) 0.89 (0.85, 0.93)
Unknown 331/187 0.64 (0.55, 0.74) 0.75 (0.64, 0.88) 0.82 (0.70, 0.96) 0.75 (0.64, 0.88)
Remoteness (residence):
Major city 8439/6164 1.00 1.00 1.00 1.00
Inner regional 4425/3315 1.07 (1.03, 1.12) 0.99 (0.93, 1.04) 0.99 (0.93, 1.05) 0.98 (0.93,1.04)
Outer regional 1943/1459 1.09 (1.03, 1.15) 0.96 (0.88, 1.05) 0.98 (0.89, 1.07) 0.95 (0.87, 1.04)
Remote/very remote 207/144 0.94 (0.80, 1.10) 0.84 (0.69, 1.02) 0.89 (0.74, 1.07) 0.89 (0.74, 1.07)
SES quintile (SEIFA)
(residence):
1 (least disadvantaged) 2403/1716 1.00 1.00 1.00 1.00
2 2486/1810 1.05 (0.98, 1.11) 1.04 (0.96, 1.12) 1.04 (0.96, 1.13) 1.04 (0.96, 1.12)
3 3206/2391 1.11 (1.05, 1.18) 1.02 (0.93. 1.11) 1.04 (0.96, 1.14) 1.03 (0.95, 1.13)
4 3698/2768 1.12 (1.06, 1.18) 1.01 (0.92, 1.10) 1.03 (0.94, 1.13) 1.02 (0.93, 1.12)
5 (most disadvantaged) 3221/2397 1.09 (1.03, 1.16) 1.06 (0.97, 1.16) 1.07 (0.97, 1.17) 1.06 (0.97, 1.16)
Country of birth:
Australia 9796/7369 1.00 1.00 1.00 1.00
Other-English speaking 1853/1408 1.02 (0.96, 1.07) 1.00 (0.94, 1.05) 0.98 (0.92, 1.03) 0.98 (0.92, 1.04)
Other-not English speaking 3029/2203 0.90 (0.86, 0.94) 0.91 (0.87, 0.96) 0.88 (0.84, 0.92) 0.88 (0.84, 0.93)
Unknown 336/102 0.30 (0.24, 0.36) 0.31 (0.25, 0.38) 0.36 (0.29, 0.45) 0.39 (0.31, 0.48)
Lung location:
C340 (main bronchus) 1315/1112 1.00 1.00 1.00 1.00
C341 (upper lobe) 5446/3718 0.61 (0.58, 0.65) 0.64 (0.60, 0.68) 0.68 (0.64, 0.73) 0.78 (0.73, 0.84)
C342 (middle lobe) 614/408 0.59 (0.53, 0.66) 0.60 (0.54, 0.67) 0.66 (0.59, 0.73) 0.75 (0.67, 0.84)
C343 (lower lobe) 2991/2035 0.61 (0.57, 0.66) 0.64 (0.60, 0.69) 0.70 (0.65, 0.75) 0.83 (0.77, 0.89)
C348 (overlapping) 143/98 0.66 (0.53, 0.81) 0.66 (0.53, 0.83) 0.69 (0.54, 0.87) 1.00 (0.80, 1.26)
C349 (not specified) 4505/3711 1.04 (0.97, 1.10) 1.01 (0.94, 1.08) 0.89 (0.83, 0.95) 0.93 (0.87, 1.00)
Histology type:
Adenocarcinoma 4394/2954 1.00 1.00 1.00 1.00
Squamous cell carcinoma 2645/1776 0.98 (0.92, 1.03) 0.91 (0.86, 0.96) 1.06 (1.00, 1.13) 1.05 (0.99. 1.11)
Large cell carcinoma 5230/4274 1.59 (1.51, 1.66) 1.39 (1.33, 1.46) 1.43 (1.37, 1.50) 1.27 (1.21, 1.34)
Other/unknown 2745/2078 1.31 (1.24, 1.38) 1.44 (1.08, 1.21) 1.16 (1.09, 1.23) 1.04 (0.98, 1.10)
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Table 2: Sub-hazard ratios (SHR) (95% confidence limits) for cumulative probability of death from lung cancer
among New South Wales cases diagnosed in 2003-2007 continued
CHARACTERISTIC  NUMbERS UNADjUSTED ADjUSTED   ADjUSTED  ADjUSTED 
 (CASES/LUNG SHR SHR** SHR*** SHR****
 CANCER DEATHS)
Charlson co-morbidity 
score:
0 5740/4149 1.00 1.00 1.00 1.00
1+ 7420/5586 1.20 (1.16, 1.25) 1.05 (1.01, 1.10) 1.05 (1.01, 1.09) 1.03 (0.99, 1.08)
Unknown 1854/1347 0.95 (0.90, 1.00) 0.93 (0.88, 0.99) 0.95 (0.90, 1.01) 0.95 (0.90, 1.01)
Extent of disease:
Localised 3381/1785 1.00  1.00 1.00
Regional 2475/1645 1.45 (1.36, 1.54)  1.48 (1.38, 1.58) 1.44 (1.34, 1.54)
Distant 5638/5122 3.42 (3.24, 3.62)  3.18 (3.00. 3.37) 2.39 (2.25, 2.53)
Unknown 3520/2530 1.62 (1.53, 1.72)  1.39 (1.31, 1.48) 1.05 (0.99, 1.12)
Resection:
None 12774/10420 5.66 (5.14, 6.22) 3.94 (3.57, 4.35)
Segmental 462/111 0.87 (0.72, 1.07) 0.86 (0.70, 1.04)
Wedge 190/68 1.36 (1.08, 1.72) 1.29 (1.03, 1.63)
Lobectomy 1384/380 1.00 1.00
Pneumonectomy 204/103 1.95 (1.62,2.35) 1.64 (1.35, 1.98
*Data source: NSW Cancer Registry; **Adjusted for other variables in Table 2 (+ Local Health District of residence) (except extent 
of disease and resection); ***Adjusted for other variables in Table 2 (+ Local Health District of residence) (except resection); 
**** Adjusted for all other variables in Table 2 (+ Local Health District of residence)
(Table 1). Also compared with adenocarcinomas, squamous 
cell and large cell carcinomas had fewer resections for 
localised NSCLC, with adjusted relative odds of 0.60 (0.48, 
0.75) and 0.15 (0.12, 0.20) respectively (Figure 1), but 
resection type did not vary (p=0.373). Case fatality was 
elevated for large cell carcinomas (Table 2).
EOD
Cases with regional and distant spread had higher risk of LC 
death than localised cases (Table 2).
Resection type
Risks of LC death were highest for non-resected cases 
(Table 2). Compared with lobectomy cases, risk of LC death 
was higher for those having a pneumonectomy or wedge 
resection. Statistically significant differences were not 
evident between cases having lobectomies and segmental 
resections (adjusted SHR for segmental resection=0.92 
(0.72, 1.19)) (Table 3).
By service characteristics (resection cases/localised 
and regional EOD only)
Emergency presentation
Cases presenting as an emergency at time of diagnosis had 
an elevated risk of LC death but this could have occurred by 
chance (adjusted SHR=1.09 (0.60, 1.97)) (Table 3).
Time from diagnosis to surgery
Unadjusted analysis indicated higher case fatality with 
longer time to surgery, but the adjusted model did not 
indicate a significant difference (Table 3).
Hospital resection volume
While SHRs were lower when numbers of lung resections 
were in the top two of three volume categories, confidence 
intervals encompassed 1.00 and differences were attrib-
utable to chance (Table 3).
Discussion
NSWCR and administrative data provide similar statistical 
profiles for LC to international research evidence, lending 
credibility to findings. They include lower odds of surgical 
resection of localised NSCLC for older people and use of 
more conservative resection types, likely reflecting  accom-
modations for reduced physiological capacity. [18] Older 
people also had a higher case fatality from LC, probably 
due to higher levels of co-morbidity and frailty and lower 
resection rates for localised NSCLC. [18]
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The lower EOD at diagnosis in older patients is contrary to 
patterns seen for many cancers, [15] but accords with results 
of earlier United States lung studies. [16,17] While reasons 
are unknown, it could reflect earlier detection from regular 
medical attention for tobacco-related respiratory and other 
comorbidity in older people. Also, less intensive diagnostic 
investigation of older cases may have led to under detection 
of more distant disease.
More conservative resections and risk of LC death applied 
for females than males for localised NSCLC, as reported 
in other studies. [19,20] Although this was not explained 
by differences in modelled variables, the measure of co-
morbidity was blunt and residual confounding from higher 
levels of tobacco-induced and other co-morbidity could 
have led to an artificial elevation of deaths in males. [3]
Table 3: Sub-hazard ratios (SHR) (95% confidence limits) for cumulative probability of death from lung cancer among 
non-small cell cases diagnosed with localised or regional extent of disease in New South Wales in 2003-2007 and 
treated by resection within six months of diagnosis*
Competing risk regression
CHARACTERISTIC  NUMbERS (CASES/LUNG UNADjUSTED SHR ADjUSTED SHR**  
 CANCER DEATHS)
Extent of disease:
Localised 1168/213 1.00 1.00
Regional 766/312 2.71 (2.28, 3.22) 2.52 (2.09, 3.03)
Resection type:
Segmental 395/85 0.84 (0.66, 1.06) 0.92 (0.72, 1.19)
Wedge 146/48 1.44 (1.07, 1.93) 1.60 (1.17, 2.21)
Lobectomy 1222/310 1.00 1.00
Pneumonectomy 171/82 2.08 (1.64, 2.64) 1.57 (1.19, 2.09)
Emergency attendance:
No 1889/511 1.00 1.00
Yes 45/14 1.09 (0.63,1.86) 1.09 (0.60, 1.97)
Time from diagnosis to
resection (months):
<1 844/200 1.00 1.00
1-2 915/264 1.23 (1.02, 1.47) 1.02 (0.84, 1.24)
3-6 175/61 1.60 (1.20, 2.13) 1.12 (0.81, 1.55)
Hospital resection volume 
per year:
<16 626/178 1.00 1.00
16-55 671/179 0.92 (0.75, 1.13) 0.87 (0.70, 1.07)
>55 637/168 0.90 (0.73, 1.11) 0.87 (0.68, 1.12)
*Data source: NSW Cancer Registry
**Adjusted for: other variables in Table 3, age at diagnosis; sex; public/private status; remoteness of residence; SES quintile;
Local Health District of residence; country of birth; lung location of cancer; histology type; and Charlson co-morbidity
Private health insurance was associated with more localised 
EOD, which may reflect higher SES. Higher SES Danish lung 
cancer cases have also shown higher odds of more localised 
EOD. [21] New South Wales patients with private insurance 
had higher odds of resection for localised NSCLC and were 
more likely to have a lobectomy than more conservative 
wedge or segmental resections. Similar results have been 
reported for NSCLC in North America. [22] The privately 
insured also had a lower risk of LC death which accords 
with North American evidence. [23] Statistical modelling 
indicated that this was not explained in New South Wales 
by more localised EOD at diagnosis, higher resection rates 
for localised NSCLC or a higher ratio of lobectomies to 
conservative procedures among the privately insured.
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The presence of more advanced EOD at diagnosis among 
patients born in non-English speaking countries was a novel 
finding. BreastScreen data show that women from culturally 
and linguistically diverse backgrounds have lower screening 
participation. [24] This may be part of a broader pattern 
where cultural and language barriers reduce or delay use of 
diagnostic and related health services.
Despite this difference, patients born in non-English 
speaking countries had a lower recorded risk of LC death 
than the Australian born. This may be due to a greater 
residential proximity to specialist treatment centres in 
major cities or alternatively a healthy migrant effect. It is 
also possible that underrecording of deaths could occur 
if significant numbers returned to birth countries in the 
terminal stages of their disease, such that their deaths were 
not recorded in Australia.
Reasons for earlier EOD in remote/very remote areas are not 
known and run counter to data for other populations. [25] 
Lower access to specialised diagnostic services in these areas 
may have reduced detection of more advanced disease. An 
elevation in case fatality was not suggested in remote/very 
remote regions, which accords with a study of United States 
Medicare data. [26]
Resection rates for localised NSCLC were lower for lower 
than upper SES groups in New South Wales, as observed 
in other populations, [27] potentially due to more limited 
service access. While United States research has indicated 
lower survivals in lower SES groups, [27] poorer survivals 
were not indicated in lower SES areas of New South Wales in 
multivariable analyses.
Patients with higher co-morbidity had fewer resections for 
localised NSCLC and their resections were more conservative, 
as found in other populations. [21] This may reflect attempts 
to avoid undue surgical risk. It was anticipated that co-
morbidity would be predictive of risk of LC death, [28] but 
only a weak relationship was observed, potentially due to 
the bluntness of the co-morbidity measure.
Cancers of pulmonary lobes had higher odds of localised 
EOD than cancers of the main bronchus, possibly reflecting 
greater visibility in imaging. Higher odds of resection for 
localised NSCLC presented for those located in pulmonary 
lobes than the main bronchus where more extensive and 
complex surgery may carry greater risks, especially for 
patients with low cardiopulmonary reserve. [29] Risk of LC 
death was lower for pulmonary lobe lesions than for those in 
the main bronchus, as reported elsewhere. [29]
Compared with adenocarcinomas, squamous cell lesions 
had higher odds and large cell lesions lower odds of localised 
EOD. Squamous cell and large-cell lesions were less likely to 
be treated by resection. Squamous cell carcinomas are often 
located centrally where surgery may be more difficult. [29] 
Risk of LC death was highest for large cell carcinomas, likely 
due to more aggressive biology. [29] Predictably, advanced 
EOD was strongly predictive of risk of LC death. For resection 
cases with localised or regional disease, a higher risk of 
LC death with longer time to surgery was evident in the 
unadjusted analysis, but not after co-variable adjustment.
The highest case fatality applied to non-resected cases. This 
may reflect a causal association for localised NSCLC, but 
also residual confounding. Compared with those having 
a lobectomy, risk of LC death following wedge resection 
was higher. Lobectomy would often be the surgery type 
of choice in treatments of localised NSCLC with curative 
intent, [8-10] which may explain the better outcomes for 
lobectomy cases. The lack of a significant difference in 
outcomes between lobectomies and segmental resections 
is consistent with earlier United States findings for early EOD 
NSCLC. [30,31]
While risk of LC death was lower when hospital numbers 
for lung resections were in the top two of three volume 
categories, differences were in the range attributable to 
chance. Further investigation is needed into relationships 
between surgical volume within resection types and by sub-
group of patients.
The present data are observational, not experimental, and 
sometimes of sub-optimal quality, as seen for co-morbidity. 
Nonetheless findings generally accord with the international 
evidence, which adds to their credibility in the New South 
Wales setting. The potential for these relationships to be 
causal and modifiable needs to be considered by the clinical 
community, along with relevant interventions.
Example questions arising from the present study include: 
(1) Is the best balance being achieved between resection 
and non-resection to accommodate age-related frailty and 
co-morbidity? 
(2) Are there modifiable causal factors for improving survival 
outcomes for public patients? 
(3) Could more advanced EOD in patients born in non-
English speaking countries be decreased by reducing 
cultural and language barriers to services? 
(4) Is the best balance being achieved between optimal 
therapy and accommodations for co-morbidity? 
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(5) Could the higher risk of LC death for cancers of the main 
bronchus be reduced by up-skilling or referral to higher-
volume centres? 
(6) Do opportunities exist for earlier treatment to increase 
survival? (7) Could survivals be increased through greater 
use of lobectomies? (8) Are segmental resections an effective 
substitute for lobectomies for some patients?
Conclusions
Linked registry and administrative data can increase system-
wide understanding of health service delivery and outcomes. 
They prompt questions that could be workshopped with a 
view to achieving better outcomes. Linked data can provide 
useful input for administrative decision-making.
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